Source:http://linkedlifedata.com/resource/pubmed/id/14726295
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-4-9
|
pubmed:abstractText |
5-Lipoxygenase (5-LO) and its downstream leukotriene products have been implicated in the development of pulmonary hypertension. In this study, we examined the effects of 5-LO overexpression in rat lungs on pulmonary hypertension using a recombinant adenovirus expressing 5-LO (Ad5-LO). Transthoracic echocardiography and right heart catheterization data showed that 5-LO overexpression in the lung did not cause pulmonary hypertension in normal rats; however, it markedly accelerated the progression of pulmonary hypertension in rats treated with monocrotaline (MCT). An increase in pulmonary artery pressure occurred earlier in the rats treated with MCT + Ad5-LO (7-10 days) compared with those treated with control vector, MCT + adenovirus expressing green fluorescent protein (AdGFP), or MCT alone (15-18 days). The weight ratio of the right ventricle to left ventricle plus septum was higher in the MCT + Ad5-LO group than that of the MCT + AdGFP or MCT group (0.45 +/- 0.08 vs. 0.35 +/- 0.03 or 0.33 +/- 0.06). Lung tissue histological sections from MCT + Ad5-LO rats exhibited more severe inflammatory cell infiltration and pulmonary vascular muscularization than those from MCT + AdGFP- or MCT-treated rats. Administration of 5-LO inhibitors, zileuton or MK-886, to either MCT- or MCT + Ad5-LO-treated rats prevented the development of pulmonary hypertension. These data suggest that 5-LO plays a critical role in the progression of pulmonary hypertension in rats and that the detrimental effect of 5-LO is manifest only in the setting of pulmonary vascular endothelial cell dysfunction.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0363-6135
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
286
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
H1775-84
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:14726295-Animals,
pubmed-meshheading:14726295-Arachidonate 5-Lipoxygenase,
pubmed-meshheading:14726295-Drug Synergism,
pubmed-meshheading:14726295-Gene Transfer Techniques,
pubmed-meshheading:14726295-Heart Septum,
pubmed-meshheading:14726295-Heart Ventricles,
pubmed-meshheading:14726295-Hypertension, Pulmonary,
pubmed-meshheading:14726295-Lung,
pubmed-meshheading:14726295-Male,
pubmed-meshheading:14726295-Monocrotaline,
pubmed-meshheading:14726295-Myocardium,
pubmed-meshheading:14726295-Organ Size,
pubmed-meshheading:14726295-Rats,
pubmed-meshheading:14726295-Rats, Sprague-Dawley,
pubmed-meshheading:14726295-Time Factors,
pubmed-meshheading:14726295-Tissue Distribution
|
pubmed:year |
2004
|
pubmed:articleTitle |
Effect of 5-lipoxygenase on the development of pulmonary hypertension in rats.
|
pubmed:affiliation |
Department of Surgery, Boston University School of Medicine, Boston, MA 02118, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|